Some early reports showed the ability of type I IFN to boost HLA class-I expression and simultaneous tumor antigens presentation to CD8 T, leading to a better immune recognition and cytotoxic effect on cancer cells [33,34]. The gene discussed is CD8A; the disease is cancer.